Immunostimulating molecules with a broad-spectrum antiviral activity : a proof of concept in non-human primate models

STING 2.0 est accrédité par Lyonbiopôle

Identity card

Global budget: 987 k€

Public funding: 449 k€

Public funders: ANR, Agence Nationale de la Recherche

Call for projects: ANR (ANR2011 - RPIB)

Year start: 2011

Completed project

Accredited by the French competitiveness cluster Lyonbiopôle

Strategic business area: Human Medicines

Application fields: Infectious diseases

Technological approaches / Keywords: Cell model / Animal model, Functional Screening / Drug discovery

Stage of development at the beginning of the project: Discovery


We have identified chemical compounds that stimulate the antiviral immune response and efficiently blunt viral replication in vitro. We need to establish a proof of concept of their antiviral activity in vivo. Since our lead molecules are only active in primate cells,  these compounds will be tested in macaques when challenged with the human respiratory syncytial virus (hRSV). Because this virus replicates in macaque airways, this represents a suitable model to establish a proof of concept for the therapeutic activity of our molecules.


Since our molecules are only active in primate cells, our STING 2.0 project aims at testing our lead molecules in macaques in collaboration with Cynbiose (Marcy l'Etoile), one of the only platforms in Europe to offer non human primate models for use by private and public companies involved in biomedical research, drug discovery and development activities. The antiviral activity of our molecules will be tested against the human respiratory syncytial virus (hRSV).

Innovative assets
Actual results

Innovative assets

There is currently no chemical treatment available against hRSV or related viral infections. The chemical compounds that we isolated have a unique mode action: they inhibit viral growth by stimulating the innate immune response of host cells. Besides, and after several rounds of chemical optimization, the half maximal inhibitory concentration of these molecules is in the nM range. We expect they will efficiently decrease or even block hRSV replication in vivo.